Court rules Canadian drug regulators cannot control generics' prices

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Court rules Canadian drug regulators cannot control generics' prices

Home/Policies & Legislation | Posted 27/06/2014 0 Post your comment

Canada’s Patented Medicine Prices Review Board (PMPRB) has been told that it has no jurisdiction over the pricing of generics.

The country’s Federal Court ruled in cases brought against the PMPRB by Sandoz Canada and Ratiopharm (now Teva Canada) that the companies were not ‘patentees’. Therefore, the PMPRB ‘has no power’ to order the companies to comply with the Act and Regulations.

The PMPRB had claimed that Sandoz and Ratiopharm came under the definition of ‘patentees’ because they both sold medicines that were patented, thus giving the PMPRB the jurisdiction to demand that they file pricing information and to set prices on their products. The PMPRB came to this conclusion based on the fact that Sandoz is a subsidiary of originator company Novartis and that Ratiopharm had a license for its salbutamol inhaler (Ratio HFA) from originator company GlaxoSmithKline.

The Canadian Federal Court, however, in its rulings of 27 May 2014, disputed this claim. The court stated that ‘while the federal government can regulate patents of invention, it has no overall jurisdiction to regulate the price of generic versions of patented medicines.’ The court added that ‘the mere fact that a subsidiary or generic company sells a version of a patented medicine (even under contract) is insufficient to bring it within the definition of a patentee’.

The court also overturned the PMPRB’s claim that Ratiopharm was selling its salbutamol inhaler (Ratio HFA) at an excessive price and that Ratiopharm must pay damages of CA$65,898,842.76. This demand from the PMPRB came as a result of Ratiopharm’s decision to increase the price of its inhaler from CA$4.50 to CA$7.50 in line with its competitors, even though this was still CA$5 under the price of the originator product (Ventolin HFA).

‘The decision means that generic drugmakers who do not hold patents themselves and do not exercise monopoly power need not file price information with the Board,’ according to Gavin MacKenzie of Davis LLP, who represented Ratiopharm and Sandoz.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Canada Federal Court, Financial Post